http://www.alliedminds.com/

"Allied Minds is an innovation company that forms, funds, manages and builds startups based on early-stage technology originating from U.S. universities and federally funded research institutions. We created a new business model for overcoming early-stage development gap between basic research and commercial development. Our investors are aligned with our vision that cutting-edge invention is an attractive, yet under-developed, asset class. We review numerous ideas but only select opportunities with potential to deliver outsized returns. We create subsidiaries led by seasoned management who know how to turn academic breakthroughs into commercial products and then take them to market. We provide our subsidiaries with capital resources, from seed to self-sustainment. Our aim is to promote growth, generate jobs, foster innovation and create societal benefit."

Allied Minds Announces Half-Yearly Results

http://www.moneyam.com/action/news/showArticle?id=4875343

HY14 Financial Highlights

· Net cash and cash equivalents at 30 June 2014: $228.5m (FY13:$104.6m)

· Revenue: $2.9m (HY13: $0.7m)

· Net loss: $27.2m (HY13: $17.6m), of which $21.9m attributable to Allied Minds (HY13: $13.6m)

"The successful completion of the IPO marks the beginning of an exciting new phase of growth and opportunity for Allied Minds and our diversified portfolio of 20 businesses. We are pleased with the positive response that we received from investors to the IPO, and look forward to enhancing and accelerating our efforts to commercialise the innovative science and technologies from our extensive network of partners at U.S. universities and government research institutions."

One of the few IPO's which has done well since float recently. Up another 6% today.

Not far from the £3 mark. I think 320p was the last broker target I saw.

Nice find Harry - I wish I'd found the thread in July!

Last/only broker :- 08 Aug 14 Jefferies International Buy 298.50 - 320.00 Initiates/Starts

StockMarketWire.com
Allied Minds, an innovative US science and technology development and commercialisation company, has announced the launch of Novare Pharmaceuticals.

Novare is a biotechnology company focused on developing therapeutic products that help the body replenish and rebuild itself using its own tissue through the modulation of RHAMM. Modulation of RHAMM is also of benefit in inflammatory diseases such as Bronchopulmonary Dysplasia (BPD).

Novare is an expansion of the Allied Minds subsidiary previously called ProGDerm, which is developing a dermal filler for aesthetic applications that works via the modulation of the Receptor for Hyaluronan Mediated Motility, or RHAMM.

This research is being led by Dr. Eva Turley, an oncology scientist at the London Health Sciences Centre (LHSC) in London, Ontario, in collaboration with MJ Bissell, a world-renowned cell biologist at Lawrence Berkeley National Laboratories in Berkeley, California.

Turley and colleagues have now uncovered the potential for additional applications of RHAMM modulation that may help solve some of today's biggest medical challenges, including arthritis, fibrotic diseases such as Bronchopulmonary Dysplasia (BPD) in premature infants and Idiopathic Pulmonary Fibrosis (IPF), and the reduction and possible elimination of keloid scars.

This breakthrough in tissue engineering may also provide an opportunity to regenerate and reconstruct women's breasts after a mastectomy through the localized stimulation of the body's own adipocyte (fat) stem cells. Novare has licensed from LHSC additional RHAMM compounds discovered by Dr. Turley, who is also serving as Novare's Chief Scientist, and Dr. Leonard Luyt, a peptide chemist at LHSC, allowing the company to more than double its library of RHAMM-binding peptides - and increase potential applications. Novare chief executive Michael Delmage said: "We are excited by the opportunity to further explore the potential therapeutic applications of RHAMM modulation technologies as the studies conducted to date show promising, medically relevant, drug-induced biological responses."

StockMarketWire.com
Allied Minds subsidiary Spin Transfer Technologies has raised $70m to accelerate commercialisation of its innovative computer memory technology. STT's patented OST-MRAM technology is a disruptive innovation in the field of spin-transfer-based MRAM devices by enabling faster switching speeds, lower power operation, reduced manufactured device cost and scalability to smaller lithographic dimensions.

OST-MRAM's application areas can potentially address large parts of the semiconductor market - in particular, the standalone memory markets and the embedded memory market in logic, microprocessors/microcontrollers and analog integrated circuits.

Woodford Investment Management (WIM) led this round of financing, demonstrating its continued support for the commercialization model of academic research pioneered in the U.S. by Allied Minds. In addition, Invesco Asset Management (Invesco) increased its stake and maintains its position as the largest institutional investor in the Fremont, California-based company. SandAire, a private wealth investment fund in London, joined the investor group with its participation in the financing.

StockMarketWire.com
Allied Minds is entering into an exclusive, worldwide licensing agreement with Columbia University that has led to the formation of a new subsidiary, Seamless Devices, Inc.

Seamless Devices is developing applications for a novel technique in analog signal processing that will make it possible to produce high-performance signals even as transistors are scaled down in size deep into the nanoscale.

The technology, developed in the laboratory of Columbia University Electrical Engineering Professor Peter Kinget, serves a wide range of applications across several industries, including consumer electronics, telecommunications hardware, instrumentation, network hardware, healthcare devices, transportation and military systems.

Appointment of Joint Broker
Allied Minds plc (LSE: ALM), an innovative U.S. science and technology development and commercialisation company, is pleased to announce that it has appointed Numis Securities Limited as joint Corporate Broker to the Company, alongside Jefferies Hoare Govett, with immediate effect.

SciFluor Life Sciences Awarded U.S. Patent for Integrin αvβ3 Inhibitors Designed for the Topical Treatment of Retinal Disease
· Patent-protected topical integrin antagonist could potentially revolutionize retinal disease therapy.

· Addressable markets include wet Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME).

· Issuance of first patent validates SciFluor's innovative approach to small molecule drug discovery by the strategic incorporation of fluorine.


Cambridge, Mass. (Dec. 4, 2014) - SciFluor Life Sciences, LLC, an emerging clinical stage biopharmaceutical company that creates innovative therapeutics for patients with ophthalmologic and neurologic disease, announced today that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8,901,144 with claims covering the novel compound SF0166. SciFluor's SF0166 is a small molecule integrin antagonist designed to treat retinal disease, including Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME), via topical administration to the eye.

Topical administration of medications (eye drops) for treating the retina in order to eliminate the need to inject compounds to the back of the eye has been considered an enormous challenge until now. Current treatments require repeated injections into the back of the eye in order to get enough of the drug where it is needed. A drug that could localize in the back of the eye after administration as an eye drop would remove the need for repeated injections. To date, no topically administered drug has been approved for these indications.

Ben Askew, PhD, Vice President of Research, said, "The issuance of the patent covering SF0166 provides validation of our fluorine-centered approach to rapidly bringing new transformational therapies to patients with serious illnesses. SF0166 demonstrates how the appropriate fluorine-containing modifications can improve the physical properties of a molecule to address the challenge of getting enough drug to the back of the eye without injections."

Dr. Askew is the lead on the SF0166 therapeutic program, which is targeted to treat both wet Age-related Macular Degeneration (AMD) as well as Diabetic Macular Edema (DME).

"The scientific depth of this team and the team's ability to rapidly evolve this candidate and to obtain an issued patent protecting this lead compound in such an enormous field of retinal disease is highly impressive. We are excited to advance this program. This is the first of many opportunities at SciFluor that we are pursuing to strategically capitalize on the transformational power of fluorine," said Omar Amirana, MD, SciFluor's Chief Executive Officer and Senior Vice President at Allied Minds.

SciFluor is a subsidiary of Allied Minds (LSE: ALM), an innovative U.S. science and technology development and commercialization company.

330p. Pushing into new territory!

StockMarketWire.com
Allied Minds subsidiary SciFluor Life Sciences has been awarded a US patent covering the novel compound SF0034, a potent and selective neuronal potassium channel activator, designed to be a significantly improved version of the first-in-class KCNQ2/3 activator drug, ezogabine (POTIGA).

POTIGA was approved in 2011 for treatment of partial-onset epilepsy in adults, but its clinical use was severely restricted in 2013 due to latent toxicities which are not thought to be associated with its mechanism of action.

Numis note today:
"US universities and federal research laboratories spend over $170bn pa on research, and Allied Minds has built a network of over 60 such organisations from which it identifies novel IP and technologies. It forms companies around this IP, providing funding, management and legal and back office support for c.80-100% of the equity. Allied Minds has formed 21 subsidiaries to-date, with its holdings valued around $411m and with another c.$175m cash able to be deployed. The company has almost $250m of capital to invest in its existing portfolio and to develop new companies, so we believe that it is well capitalised to continue to build value. We value Allied Minds at 455p/share, implying 2.5x based on an assumption of 10-year IRR of 26% (compared to c.60% historical IRR), and initiate research coverage with a Buy rating.
The largest two holdings are:
Spin Transfer Technologies (STT) has developed a next-generation memory technology, which potentially has speed, reliability, energy consumption and cost benefits over incumbent technologies – we estimate that the addressable market is over $70bn. The company has already made significant technical progress and has recently been funded for the next phase of development, which should result in prototype products shipping in late CY15. It is most likely that an IP business model will be used, where STT licenses the technology to existing players in the memory market and earns royalties on chip sales (similar to ARM). However, the company may be acquired by one of those players if momentum around its technology continues to build.
RF Biocidics (RFB). With one in six people per year suffering from food-borne illnesses, and increasing regulatory emphasis on prevention, we believe that food disinfection will remain a growing trend. Existing disinfection methods have significant drawbacks, so RF Biocidics has developed a new system that uses radiofrequency. This has been integrated into two products that have already been sold to some major food producers.
Forecasts. Allied Minds' control over its subsidiaries means it consolidates their accounts, thus showing investment as operating and investing cash outflows. We model STT and RFB together generating $60m of revenue by 2018, which helps to offset an investment rate we model at $50-60m pa. Key risks include unanticipated technical hurdles at STT and slower commercial adoption of RFB's products.

Now more than doubled since the float. Currently 435p mid .

Has now passed the Numis price target of 455p. Possibly getting a little ahead of itself now? Consolidation (pause for breath) would make me happy now!

Looks like you have been on your own here HARRY , good pick .

Thanks jimmy. Going like a train! Trouble is, I have no idea why! No news, yet sp now surged past the £6 level.

Yes - fancy keeping these to yourself Harry! :-)

5th Sept was your last look skinny and you passed! On my part this is luck more than judgement! It's going up relentlessly but I don't really know why!!! Even the last broker note is not particularly enlightening on how it has valued the stock.

Well he posted 18 times over the last 6 months and we ignored him !!

Possibly now due to this:
"26-Feb-2015
Optio Labs Names Former Samsung Executive Bryan Glancey as Chief Technology Officer."

Though even ALM are cautious about their strategy!
"Allied Minds Forward-Looking Statement
This press release contains statements that are or may be forward-looking statements, including statements that relate to the company’s future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the company’s regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law, regulatory requirement, the Listing Rules and the Disclosure and Transparency Rules, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise."